Active, Not Recruiting
Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)
NCT06357988
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +20 more
- Locations
-
- ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States